Sean McElligott, MS

Business of Pathways

Health Care as a Preexisting Financial Condition: Individual Costs and Societal Benefits

12/17/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

While societally we are still debating the best way to finance health care, we do all agree that when a therapy is available to alleviate illness and suffering, we should find a way to make it available to patients....

While...

12/17/2019

Journal of Clinical Pathways

Business of Pathways

Broadening the Value Assessment Paradigm: Including the Value of Hope and the Value of Insurance

10/18/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

*/ /*-->*/ While social media is all about sharing, very little personal preference data makes its way into health plan contracting around specific interventions and pathway programs today. As a result, the...

...

10/18/2019

Journal of Clinical Pathways

Business of Pathways

Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures

06/18/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...

Cell...

06/18/2019

Journal of Clinical Pathways